Skip to main content
SpringerLink
Log in

Hormontherapie in der Peri- und Postmenopause und Malignomrisiko

Hormone therapy during peri- and postmenopause and cancer risk

  • Leitthema
  • Published:
Gynäkologische Endokrinologie Aims and scope

Zusammenfassung

Das Mammakarzinom, das Endometriumkarzinom und das Ovarialkarzinom sind hormonabhängige Malignome. Östrogene und Gestagene können proliferativ auf das Tumorwachstum wirken. Die Hormontherapie in der Peri- und Postmenopause kann das Risiko für hormonabhängige Malignomerkrankungen steigern oder senken. Dieser Beitrag zeigt den Einfluss einer Hormontherapie auf das Risiko für Mamma-, Endometrium-, Ovarial-, Zervix- und kolorektale Karzinome.

Abstract

Many human neoplasms, in particular gynecological cancer, are hormone-dependent malignancies. Whether hormones, like estrogens and progestogens, are cancer causing or cancer stimulating is currently under discussion. Similar to endogenous hormones, hormone therapy of peri- and postmenopause under different conditions can also lead to tumor growth or tumor reduction. This article provides evidence of the influence of peri- and postmenopausal hormone therapy on gynecological and colon cancer risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Dietel M, Lewis MA, Shapiro S et al (2005) Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Hum Reprod 20(8):2052–2060

    Article  CAS  PubMed  Google Scholar 

  2. (n a) (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 350(9084):1047–1059. Erratum in: Lancet 350(9089):1484

  3. Rossouw JE, Anderson GL, Prentice RL et al (2002) Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333

    Article  CAS  PubMed  Google Scholar 

  4. Heiss G, Wallace R, Anderson GL et al (2008) Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 9:1036–1045

    Article  Google Scholar 

  5. Flesch-Janys D, Slanger T, Mutschelknauss E et al (2008) Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. Int J Cancer 123(4):933–941

    Article  CAS  PubMed  Google Scholar 

  6. Katalinic A, Rawal R (2008) Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat 107(3):427–430

    Article  CAS  PubMed  Google Scholar 

  7. Beral V (2003) Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362(9382):419–427. Erratum in: Lancet 362(9390):1160

    Google Scholar 

  8. Kenemans P, Bundred NJ, Foidart JM et al (n d) on behalf of the LIBERATE Study Group

  9. Green PK, Weiss NS, McKnight B et al (1996) Risk of endometrial cancer following cessation of menopausal hormone use (Washington, United States). Cancer Causes Control 7(6):575–580

    Article  CAS  PubMed  Google Scholar 

  10. Ortmann O, König K (2005) Hormontherapie im Klimakterium und in der Postmenopause. Deutsch Ärztebl 102(3):144–147

    Google Scholar 

  11. Hulley S, Furberg C, Barret-Connor E et al (2002) Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288(1):58–66

    Article  CAS  PubMed  Google Scholar 

  12. Beral V, Bull D, Reeves G et al (2005) Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365(9470):1543–1551

    Article  PubMed  CAS  Google Scholar 

  13. Doherty JA, Cushing-Haugen KL, Saltzman BS et al (2007) Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer. Am J Obstet Gynecol 197(2):139.e1–e7

    Article  PubMed  CAS  Google Scholar 

  14. Creasman WT, Henderson D, Hinshaw W et al (1986) Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 67(3):326–330

    CAS  PubMed  Google Scholar 

  15. Lee RB, Burke TW, Park RC (1990) Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol 36(2):189–191

    Article  CAS  PubMed  Google Scholar 

  16. Committee on Gynecologic Practice (2001) Hormone replacement therapy in women treated for endometrial cancer. Int J Gynecol Obstet 73:283–284

    Article  Google Scholar 

  17. IARC Monographs (n d) Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy. ISBN 978 92 832 1291 1 91:528

  18. Hunt K, Coleman MP (1987) The completeness of cancer registration in follow-up studies – a cautionary note. Br J Cancer 56(3):357–359

    CAS  PubMed  Google Scholar 

  19. Anderson GL, Judd HL, Kaunitz AM et al (2003) Women’s Health Initiative Investigators. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women’s Health Initiative randomized trial. JAMA 290(13):1739–1748

    Article  CAS  PubMed  Google Scholar 

  20. Lancey JV, Brinton LA, Leitzmann MF et al (2006) Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort. J Natl Cancer Inst 98(19):1397–1405

    Article  Google Scholar 

  21. Greiser CM, Greiser EM, Dören M (2007) Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis. Hum Reprod Update 13(5):453–463

    Article  CAS  PubMed  Google Scholar 

  22. Beral V, Million Women Study Collaborators, Bull D, Green J et al (2007) Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 369(9574):1703–1710

    Article  CAS  PubMed  Google Scholar 

  23. Eeles RA, Tan S, Wiltshaw E et al (1991) Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ 302(6771):259–262

    Article  CAS  PubMed  Google Scholar 

  24. Mascarenhas C, Lambe M, Bellocco R et al (2006) Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival. Int J Cancer 119(12):2907–2915

    Article  CAS  PubMed  Google Scholar 

  25. McMichael AJ, Potter JD (1980) Reproduction, endogenous and exogenous sex hormones, and colon cancer: a review and hypothesis. J Natl Cancer Inst 65(6):1201–1207

    CAS  PubMed  Google Scholar 

  26. Nanda K, Bastian LA, Hasselblad V et al (1999) Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol 93(5 Pt 2):880–888

    Article  CAS  PubMed  Google Scholar 

  27. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C et al (2004) Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 350(10):991–1004

    Article  CAS  PubMed  Google Scholar 

  28. Fournier A, Fabre A, Mesrine S et al (2008) Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J Clin Oncol 26(8):1260–1268

    Article  PubMed  Google Scholar 

  29. Chlebowski RT, Kuller LH, Prentice RL et al (2009) WHI Investigators. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 360(6):573–587

    Article  CAS  PubMed  Google Scholar 

  30. Hormontherapie in der Peri-und Postmenopause (HT) Interdisziplinäre S3-Leitlinie AWMF 015/062

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Klinik für Frauenheilkunde und Geburtshilfe, Caritas Krankenhaus St. Josef, Universität Regensburg, Landshuter Str. 63, 93053, Regensburg, Deutschland

    D. Noss &  O. Ortmann

Authors
  1. D. Noss
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O. Ortmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to O. Ortmann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Noss, D., Ortmann, O. Hormontherapie in der Peri- und Postmenopause und Malignomrisiko. Gynäkologische Endokrinologie 8, 13–16 (2010). https://doi.org/10.1007/s10304-009-0331-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10304-009-0331-8

Schlüsselwörter

Keywords

Search

Navigation